The family of herpes viruses is a large family. It includes over 100 virus types, only 8 of which are known to cause infections in humans. These include:
Despite much similarities in their structure, different herpes infections cause different symptoms. One character however common to all is their ability to persist in the host as a latent state after a primary infection. The latent virus then gets reactivated during immunodeficiency states and causes secondary infection.
Currently, only varicella zoster virus has a vaccine available against it. Adequate management of the infections is important as during pregnancy, these infections can lead to severe damage or even loss of child.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.
wdt_ID | Method | Parameter | Substrate | Species/ Antigen |
---|---|---|---|---|
626 | PCR | EURORealTime HSV-1/2 | ||
627 | IFA | antibodies against Herpes simplex virus 1 (HSV-1) IgG positive control |
||
628 | IFA | antibodies against Herpes simplex virus 1 (HSV-1) IgM positive control |
||
629 | IFA | Herpes simplex virus 1 (HSV-1) |
infected cells | EU 38 |
630 | IFA | HSV-1/HSV-2 negative control |
||
631 | WESTERNBLOT | antibodies against Herpes simplex virus (HSV) IgG positive control |
||
632 | IFA | BIOCHIP Mosaic HSV-1/HSV-2 |
2 BIOCHIPs per field: infected cells |
EU 38 |
633 | ELISA | CSQ pair of controls anti-HSV-1/2 Pool (IgG) |
||
634 | ELISA | Herpes simplex virus (HSV-1/2 Pool) |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
635 | ELISA | Herpes simplex virus (HSV-1/2 Pool) |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
636 | ELISA | Herpes simplex virus (HSV-1/2 Pool) antibody determination in CSF |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
637 | ELISA | Herpes simplex virus (HSV-1/2 Pool) incl. IgG/RF absorbent |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
638 | WESTERNBLOT | EUROLINE-WB Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2 |
Westernblot | whole antigen, SDS extract of HSV-1 plus purified gG2 |
639 | ELISA | Herpes simplex virus 1 (HSV-1) incl. IgG/RF absorbent |
antigen-coated microplate wells |
native glycoprotein C1 |
640 | ELISA | Herpes simplex virus 1 (HSV-1) |
antigen-coated microplate wells |
recombinant glycoprotein C1 |
641 | IFA | antibodies against Herpes simplex virus 2 (HSV-2) IgG positive control |
||
642 | IFA | antibodies against Herpes simplex virus 2 (HSV-2) IgM positive control |
||
643 | IFA | Herpes simplex virus 2 (HSV-2) |
infected cells | EU 38 |
644 | ELISA | Herpes simplex virus 2 (HSV-2) incl. IgG/RF absorbent |
antigen-coated microplate wells |
recombinant glycoprotein G2 |
645 | ELISA | Herpes simplex virus 2 (HSV-2) |
antigen-coated microplate wells |
recombinant glycoprotein G2 |
646 | IFA | antibodies against HHV-6 IgG positive control |
||
647 | IFA | antibodies against HHV-6 IgM positive control |
||
648 | IFA | HHV-6 | infected cells | EU 30 |
649 | IFA | HHV-6 EUROPattern | infected cells | EU 30 |
650 | IFA | HHV-6 negative control |
2023 EUROIMMUN US